Antibiotice S.A. (ATB.RO)
- Previous Close
1.7880 - Open
1.8000 - Bid 1.7960 x --
- Ask 1.8000 x --
- Day's Range
1.7800 - 1.8200 - 52 Week Range
1.7500 - 3.4400 - Volume
331,561 - Avg. Volume
206,329 - Market Cap (intraday)
1.208B - Beta (5Y Monthly) 0.09
- PE Ratio (TTM)
12.00 - EPS (TTM)
0.1500 - Earnings Date --
- Forward Dividend & Yield 0.02 (1.14%)
- Ex-Dividend Date Sep 25, 2025
- 1y Target Est
2.66
Antibiotice S.A. produces and sells medicinal products in Romania. The company offers generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system preparations; generic non-prescription medicines, including food supplements, cosmetics, and medical devices; active substances; biofertilizers; and veterinary medicines. Its products are available in the form of sterile injectable powders, capsules, tablets, ointments, gels, creams, and suppositories. It also provides active pharmaceutical ingredients. In addition, the company exports its products worldwide. Antibiotice S.A. was founded in 1955 and is headquartered in Iasi, Romania.
www.antibiotice.ro1,355
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ATB.RO
View MorePerformance Overview: ATB.RO
Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATB.RO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATB.RO
View MoreValuation Measures
Market Cap
1.21B
Enterprise Value
1.35B
Trailing P/E
11.83
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.79
Price/Book (mrq)
1.35
Enterprise Value/Revenue
1.99
Enterprise Value/EBITDA
8.82
Financial Highlights
Profitability and Income Statement
Profit Margin
14.84%
Return on Assets (ttm)
5.54%
Return on Equity (ttm)
11.74%
Revenue (ttm)
688.7M
Net Income Avi to Common (ttm)
102.2M
Diluted EPS (ttm)
0.1500
Balance Sheet and Cash Flow
Total Cash (mrq)
2.68M
Total Debt/Equity (mrq)
16.02%
Levered Free Cash Flow (ttm)
-60.04M